ClinicalTrials.Veeva

Menu
J

Johnson Dermatology | Fort Smith, AR

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

JNJ-77242113
CTP-543
Amlitelimab
LY3454738
LY3009104
Baricitinib
Ruxolitinib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 10 total trials

A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata (BRAVE-AA1)

This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the...

Active, not recruiting
Alopecia Areata
Drug: Baricitinib
Drug: Placebo

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Active, not recruiting
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo

The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/o...

Active, not recruiting
Plaque Psoriasis
Drug: Placebo
Drug: JNJ-77242113

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Active, not recruiting
Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo

The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (A...

Enrolling
Atopic Dermatitis
Drug: Placebo
Drug: LY3454738

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo controlled, 3-arm study for treatment of participant...

Enrolling
Dermatitis Atopic
Drug: Topical calcineurin inhibitors
Drug: Amlitelimab

The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).

Enrolling
Prurigo
Drug: Ruxolitinib Cream
Drug: Vehicle Cream

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Active, not recruiting
Alopecia Areata
Drug: CTP-543

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Trial sponsors

Janssen (J&J Innovative Medicine) logo
Lilly logo
Concert Pharmaceuticals logo
Incyte logo
Sanofi logo
T

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems